Harvest One Operational Update
Perth, Nov 15, 2017 AEST (ABN Newswire) - MMJ PhytoTech Limited (
ASX:MMJ) ("MMJ" or "the Company") is pleased to advise that TSX-V listed Harvest One Cannabis Inc. (CVE:HVST) ("Harvest One"), which is 59% owned by MMJ, has released an operational update on its medical and health division Satipharm AG ("Satipharm").
Satipharm's Melbourne-based distribution partner, HL Pharma Pty Ltd ("HL Pharma"), has commenced distribution of Satipharm's Gelpell-CBD(TM) capsules to approved patients in Australia.
About Harvest One Cannabis Inc.
Harvest One Cannabis Inc. (CVE:HVST) controls operations across the entire cannabis value chain through three business units, with Harvest One serving as the umbrella company over horticultural arm United Greeneries and medical arm Satipharm AG. Each business is strategically located in favourable jurisdictions with supportive regulatory frameworks in place. United Greeneries has received a Canadian medicinal cannabis cultivation licence, making Harvest One one of only a few companies globally with the capacity to commercially cultivate cannabis in a federally regulated environment.
To view the full copy of the Harvest One announcement, please visit:
http://abnnewswire.net/lnk/37W16JNJ
About MMJ Group Holdings Ltd
MMJ Group Holdings Ltd (ASX:MMJ) is a global cannabis investment company. MMJ owns a portfolio of minority investments and aims to invest across the full range of emerging cannabis-related sectors including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail. For MMJ's latest investor presentation and news, please visit: https://www.mmjphytotech.com.au/investors/
| ||
|
